Healthcare / BiotechnologyASX
$13.62
-0.59 (-4.15%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $125.4M · quality 41.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
59.2x
↑EV/EBITDA
80.7x
↑ROE
9.0%
↑Gross Margin
100.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+64.4%
FCF CAGR
+227.2%
FCF margin
194.0%
FCF / Net income
4.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $64.6M · net income $30.4M · FCF $125.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $64.6M | $64.6M | $213.2M | $231.9M | $14.6M |
| Net Income | $30.4M | $30.4M | $142.0M | $157.1M | $184000.00 |
| EBITDA | $22.0M | $22.0M | $175.6M | $199.2M | $-1.6M |
| EPS | 0.23 | 0.23 | 1.09 | 1.20 | 0.00 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | 34.0% | 34.0% | 82.3% | 85.9% | -11.0% |
| Net Margin | 47.1% | 47.1% | 66.6% | 67.7% | 1.3% |
| Balance Sheet | |||||
| Current Ratio | 76.60 | 76.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $125.4M | $125.4M | $-11.3M | $184.9M | $3.6M |
| Returns | |||||
| ROE | 9.0% | 9.0% | 39.0% | 76.5% | 0.4% |
| Valuation | |||||
| P/E | 59.22 | 59.22 | 11.23 | 20.07 | 5900.00 |
| EV/EBITDA | 80.69 | 80.69 | 8.96 | 15.74 | — |
| P/B | 5.26 | 5.26 | 4.33 | 15.37 | 26.81 |
| Growth & Yield | |||||
| Revenue Growth | -69.7% | -69.7% | -8.1% | 1493.7% | — |
| EPS Growth | -78.6% | -78.6% | -9.6% | 79966.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
73.2%
EPS terminal req.
$1.21
Spread vs growth
-151.8%
5Y implied EPS CAGR
44.4%
EPS terminal req.
$1.46
Spread vs growth
-123.0%
10Y implied EPS CAGR
26.0%
EPS terminal req.
$2.36
Spread vs growth
-104.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-2.0%
Start / end P/E
12.8x → 58.5x
EPS bridge
1.09 → 0.23
Residual
-280.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.